Literature DB >> 12165199

Diagnosis of immunodeficiency: clinical clues and diagnostic tests.

Mary E Paul1.   

Abstract

Recognition of immunodeficiency allows steps to be taken to minimize morbidity and mortality. Immunodeficiency can be secondary to viral infection, most importantly secondary to HIV-1 worldwide, medications, disruption of the usual infection clearance mechanisms, or secondary to a myriad of systemic disorders. Immunodeficiency may also be due to one of the growing list of primary immunodeficiency disorders. In infancy, lymphopenia should trigger an evaluation investigating the possibility of severe combined immunodeficiency. Evaluations of children should be done keeping in mind that normal numbers of lymphocytes are higher in children than in adults, immunoglobulin levels in children are lower than in adults in younger age groups, and antibody production in response to polysaccharide antigens is not usually fully developed in the less-than 2-year-old child.

Entities:  

Mesh:

Year:  2002        PMID: 12165199     DOI: 10.1007/s11882-002-0066-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  39 in total

Review 1.  Primary immunodeficiency diseases: an experimental model for molecular medicine.

Authors:  A Fischer
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

2.  The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter.

Authors:  K Lühn; M K Wild; M Eckhardt; R Gerardy-Schahn; D Vestweber
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

3.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

4.  Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome.

Authors:  Y Minegishi; A Lavoie; C Cunningham-Rundles; P M Bédard; J Hébert; L Côté; K Dan; D Sedlak; R H Buckley; A Fischer; A Durandy; M E Conley
Journal:  Clin Immunol       Date:  2000-12       Impact factor: 3.969

5.  Mutations in Igalpha (CD79a) result in a complete block in B-cell development.

Authors:  Y Minegishi; E Coustan-Smith; L Rapalus; F Ersoy; D Campana; M E Conley
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

6.  Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM.

Authors:  S Ferrari; S Giliani; A Insalaco; A Al-Ghonaium; A R Soresina; M Loubser; M A Avanzini; M Marconi; R Badolato; A G Ugazio; Y Levy; N Catalan; A Durandy; A Tbakhi; L D Notarangelo; A Plebani
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

7.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

Authors:  R H Buckley; S E Schiff; R I Schiff; L Markert; L W Williams; J L Roberts; L A Myers; F E Ward
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

8.  RAG mutations in human B cell-negative SCID.

Authors:  K Schwarz; G H Gauss; L Ludwig; U Pannicke; Z Li; D Lindner; W Friedrich; R A Seger; T E Hansen-Hagge; S Desiderio; M R Lieber; C R Bartram
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM.

Authors:  U Korthäuer; D Graf; H W Mages; F Brière; M Padayachee; S Malcolm; A G Ugazio; L D Notarangelo; R J Levinsky; R A Kroczek
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

10.  Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

Authors:  S M Russell; N Tayebi; H Nakajima; M C Riedy; J L Roberts; M J Aman; T S Migone; M Noguchi; M L Markert; R H Buckley; J J O'Shea; W J Leonard
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

View more
  3 in total

1.  Immune globulin intravenous (human), 5% liquid gammaplex: for replacement therapy of primary humoral immunodeficiency.

Authors: 
Journal:  P T       Date:  2011-06

2.  Privigen immune globulin intravenous (human), 10% liquid.

Authors: 
Journal:  P T       Date:  2011-08

3.  The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review.

Authors:  Rohan Ameratunga; See-Tarn Woon; Katherine Neas; Donald R Love
Journal:  Allergy Asthma Clin Immunol       Date:  2010-06-08       Impact factor: 3.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.